Wednesday, 19 June 2019

Adding bevacizumab improves overall survival in NSCLC

(HealthDay)—The addition of bevacizumab to carboplatin/pemetrexed is associated with improved overall survival among patients with advanced non-small cell lung cancer (NSCLC), according to a study published in the May issue of the Journal of the National Comprehensive Cancer Network.

* This article was originally published here